Hot-flash trials show a ~20–35% placebo response, so only placebo-controlled results count. Against that bar: black cohosh's largest independent trial (HALT) found it no better than placebo; soy isoflavones show small reductions in some meta-analyses, slowly, possibly concentrated in women whose gut bacteria produce equol; red clover pools to marginal; evening primrose, wild yam creams, maca and "hormone balancing" blends have essentially nothing. Safety isn't blank either — black cohosh carries rare liver-injury reports. Meanwhile hormone therapy reduces flashes ~75%, and non-hormonal prescriptions and CBT have real trial support. Inositol for PCOS is a different, fairer story.
The scorecard
Menopause's supplement shelf is vast because the symptom is vast and the 2002 HT scare pushed a generation toward "natural." Against placebo-controlled trials:
| Ingredient | Verdict | What trials show |
|---|---|---|
| Black cohosh | Mixed→negative | The largest independent RCT (HALT, ~350 women, 12 months) found it indistinguishable from placebo alone or in blends; earlier positive trials were smaller and lower-quality. Rare liver-injury reports add a cost side. |
| Soy isoflavones | Limited | Meta-analyses: modest flash reductions (~1–1.5/day beyond placebo) emerging over 12+ weeks; the equol subgroup (FAQ) may hold most of it. Soy foods are safe, healthy and reasonable to favor. |
| Red clover isoflavones | Insufficient | Pooled effects marginal-to-null across trials. |
| Evening primrose oil | Insufficient | Trials essentially negative for flashes; folklore does the selling. |
| Wild yam creams | None | Its diosgenin cannot become progesterone in human skin — the mechanism is a laboratory step humans don't perform. |
| Maca | Insufficient | Tiny trials, mood/libido signals, nothing solid for flashes. |
| Ashwagandha, rhodiola ("adaptogens") | Insufficient for menopause | Stress evidence doesn't transfer; menopause-specific trials are pilot-scale. |
| Magnesium, vitamin E | Insufficient | Small/negative for flashes; magnesium keeps its separate sleep/cramp uses. |
| "Hormone balance" multi-blends | Insufficient | Untrialled combinations of the rows above at undisclosed doses — plus this category's regulator findings of undeclared drugs. |
| Pollen extract (PureCyTonin-type) | Limited | A couple of small positive European trials; niche but more honest than most of the shelf. |
And the fair-story footnote from next door: inositol for PCOS shows what a supplement with genuine trial support looks like — which sharpens how this shelf reads.
The comparison the shelf avoids
Hormone therapy reduces flash frequency by ~75% in trials; fezolinetant and low-dose SSRIs/SNRIs post large, replicated effects; CBT for menopause improves interference and sleep with durable results. Every row above competes for the 0–15% band beyond placebo. A woman white-knuckling years of sweats on black cohosh is not being cautious; she is taking the least effective option on the menu at a nonzero safety price — usually because the effective menu was never properly described to her, which the menopause guide tries to fix.
The honest playbook
- Map the symptoms for 4–8 weeks (frequency, triggers, sleep cost) — the data that makes any appointment productive.
- Have the real conversation: HT suitability (the rehabilitated risk picture), non-hormonal prescriptions, CBT, local estrogen for the symptoms that progress — the treatment section previews it.
- If trying the shelf anyway: soy foods first (cheapest, healthiest version of the best-scoring row), one product at a time, 12 weeks, counted honestly against the placebo bar; skip black cohosh on the HALT-plus-liver math; skip anything "balancing hormones" by blend.
- Route the red flags — post-menopausal bleeding, breast changes — to medicine immediately; no shelf question applies.
Product-level findings for the women's-health formulas we review live in women's supplement research.
Frequently asked questions
Why is the placebo response so large in hot-flash trials?
Flashes fluctuate and regress toward the mean (women enroll at their worst), counting one's flashes changes the experience of them, and expectation genuinely modulates the neurovascular event — placebo arms reliably log 20–35% reductions over 12 weeks. That is why "my flashes halved on X" is sincere and uninformative at once, and why the table only scores placebo-subtracted effects.
What's the equol story with soy?
Soy's isoflavone daidzein becomes the more estrogen-active equol only in women whose gut bacteria carry the right enzymes — roughly 30–50% of Western women, more in Asia. Trials mixing producers and non-producers may dilute a real subgroup effect, which is the charitable reading of soy's inconsistent record. Testing equol status isn't routine; eating soy foods and judging over 8–12 weeks is the practical version.
Is black cohosh at least safe to try?
Mostly, short-term — but rare cases of significant liver injury led regulators in several countries to require warnings, so it joins the with-food, watch-for-jaundice, avoid-with-liver-disease list, and its null HALT result makes the trade unappealing. It is not estrogenic (older worry), but breast-cancer patients should still involve their oncologist before any hormonal-sphere supplement.
Are "bioidentical" compounded hormones a natural middle path?
No — compounded "bioidentical" mixes are unregulated versions of the same hormones, without the dose consistency, endometrial protection assurance or trial base of licensed HT (which itself now includes body-identical estradiol and micronized progesterone). Women wanting body-identical therapy can get the regulated kind; the compounded market sells the vocabulary without the quality control.
References
- NCCIH. Black Cohosh (2020). https://www.nccih.nih.gov/health/black-cohosh
- Office on Women's Health, U.S. Department of Health and Human Services. Menopause (2023). https://www.womenshealth.gov/menopause
- U.S. Food and Drug Administration. Dietary Supplements (2024). https://www.fda.gov/food/dietary-supplements
This page discusses supplement ingredients or categories. It may mention a commercial product, with disclosure. It is general health information, not personal medical advice. Read our editorial policy and medical review policy.